<DOC>
	<DOC>NCT01294007</DOC>
	<brief_summary>The purpose of this study is to evaluate the rate and quality of fusion of PureGen Osteoprogenitor Cell Allograft, compared to autograft bone in instrumented posterolateral fusion (PLF) procedures.</brief_summary>
	<brief_title>Radiographic Analysis Using PureGen Versus Autologous Bone in Posterolateral Fusion (PLF)</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Symptomatic lumbar degenerative disc disease in up to two contiguous levels between L1 and S1 Subjects with back and/or leg pain indicated for posterior stabilization with or without decompression at any level and posterolateral fusion (PLF) Unresponsive to conservative treatment for at least 6 months Radiographic evidence of primary diagnosis More than 2 levels requiring posterolateral fusion Spondylolisthesis greater than Grade I Prior failed fusion surgery at any lumbar level(s) Systemic or local infection in the disc or cervical spine, past or present Active systemic disease Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing Use of other bone graft, Bone Morphogenetic Protein (BMP) or bone graft substitutes in addition to or in place of those products specified BMI greater than 40 Use of post operative Spinal Cord Stimulator (SCS) Known or suspected history of alcohol and/or drug abuse Involved in pending litigation or worker's compensation related to the spine Pregnant or planning to become pregnant during the course of the study Insulindependent diabetes mellitus Life expectancy less than duration of study Any significant psychological disturbance that could impair consent process or ability to complete selfassessment questionnaires Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected steroids or prolonged use of nonsteroidal antiinflammatory drugs. Known history of hypersensitivity or anaphylactic reaction to dimethyl sulfoxide (DMSO)</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>